Self‐assembled liver organoids recapitulate hepatobiliary organogenesis in vitro

Dipen Vyas, Pedro M. Baptista, Matthew Brovold, Emma Moran, Brandon Gaston, Chris Booth, Michael Samuel, Anthony Atala, Shay Soker – 23 August 2017 – Several three‐dimensional cell culture systems are currently available to create liver organoids. In gneral, these systems display better physiologic and metabolic aspects of intact liver tissue compared with two‐dimensional culture systems. However, none reliably mimic human liver development, including parallel formation of hepatocyte and cholangiocyte anatomical structures.

Engaging hepatitis C infected patients in cost‐effectiveness analyses: A literature review

T. Joseph Mattingly, Eleanor M. Perfetto, Sophia L. Johnson – 23 August 2017 – Cost‐effectiveness analyses (CEAs) of hepatitis C virus (HCV) treatment strategies have become common, but few appear to include patient engagement or the patient perspective. The objectives of the current study were to (1) identify published HCV CEA studies that include patient input and (2) derive insights on patient‐informed variable and outcome selection to build a framework for future economic analyses of HCV.

Engaging hepatitis C infected patients in cost‐effectiveness analyses: A literature review

T. Joseph Mattingly, Eleanor M. Perfetto, Sophia L. Johnson – 23 August 2017 – Cost‐effectiveness analyses (CEAs) of hepatitis C virus (HCV) treatment strategies have become common, but few appear to include patient engagement or the patient perspective. The objectives of the current study were to (1) identify published HCV CEA studies that include patient input and (2) derive insights on patient‐informed variable and outcome selection to build a framework for future economic analyses of HCV.

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection

Nancy Reau, Michael N. Robertson, Hwa‐Ping Feng, Luzelena Caro, Wendy W. Yeh, Bach‐Yen T. Nguyen, Janice Wahl, Eliav Barr, Peggy Hwang, Stephanie O. Klopfer – 22 August 2017 – Concomitant proton pump inhibitor (PPI) use reduces plasma concentrations of certain nonstructural protein 5A inhibitors, which are key components of modern hepatitis C infection (HCV) treatments. These reduced concentrations may decrease efficacy, leading to challenging treatment failures due to the development of resistance‐associated substitutions.

Subscribe to